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http://dx.doi.org/10.1016/j.kjms.201Abstract We examined the correlation between laminin 332 and malignancy in bladder can-
cer patients, and, using a strain of invasive bladder cancer cells, determined whether laminin
332 causes bladder cancer motility and invasion. To investigate the correlation between
laminin 332 g2 distribution and patient outcome, we performed a semiquantitative immunohis-
tochemical analysis of 35 paraffin-embedded samples using the antibody D4B5, which is spe-
cific for the laminin 5 g2 chain. To evaluate the role of laminin 332 in NBT-II cell motility
and invasion, we used a scratch assay and the Boyden chamber chemoinvasion system. Tumor
stage and grade were significantly correlated with a loss of laminin 332 g2 chain from the base-
ment membrane (p Z 0.001) and its retention in the cytoplasm (p Z 0.001) (KruskaleWallis
test). KaplaneMeier survival curves revealed an association between the risk of progression
and cytoplasmic retention of the laminin 332 g2 chain. In addition, an in vitro scratch assay
showed an increase in the migration of cells treated with laminin 332 from their cluster.
The Boyden chamber assay showed that laminin 332 potentiated NBT-II cell invasion. Immuno-
histochemistry results showed that bladder cancer patients with a higher malignancyt of Urology, Korea University Hospital, 126-1, Anam-dong 5-ga, Sungbuk-gu, Seoul 136-705, South
com (J.-G. Lee).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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Effect of laminin 332 in bladder cancer 423expressed more laminin 332. The in vitro scratch and invasion assay showed that laminin 332
stimulated the motility and invasion of bladder cancer cells. The invasion assay explains the
correlation between laminin 332 expression and bladder cancer malignancy.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
To invade the surrounding tissue, tumor cells must dissolve
cellecell adhesions and transform into more migratory,
invasive cells. These changes require various signaling
pathways and molecular mechanisms. In particular, the
interaction between cancer cells and the extracellular
matrix is essential for invasion and metastasis [1]. Laminins
are basement membrane (BM) proteins that influence cell
proliferation, differentiation, adhesion, migration, and
gene expression, while maintaining epithelial cell polarity
and organization [2e5]. Specifically, laminin 332 is a com-
ponent of the epithelial cell adhesion complex in hemi-
desmosomes, anchoring fibrils, and anchoring fibers [6].
Laminin 332, which consists of a3, b3, and g2 chains, is
a major component of the BM of transitional and stratified
squamous epithelia, lung mucosa, and other epithelial
glands [7,8]. In normal tissue, laminin 332 maintains tissue
integrity, but in tumor cells, it promotes migration and dis-
semination [9]. Altered laminin 332 expression has been
reported in squamous cell carcinoma, colorectal carcinoma,
breast carcinoma, prostate carcinoma, pancreatic adeno-
carcinoma, and invasive cervical lesions [10e17]. Only a few
articles, however, have studied laminin expression in pa-
tients with bladder cancer, and none of them have inves-
tigated whether laminin 332 expression affects bladder
cancer migration [18,19]. Previously, Hindermann et al. [18]
showed that the bladder cancer stage and differentiation
clearly correlated with laminin g2 expression. However,
they could not determine whether laminin contributed to
cancer invasion through abnormal hemidesmosomes or
a reorganized extracellular matrix, and there is almost no
other research on bladder cancer and laminin.
We used human tissue to examine a correlation between
laminin 332 and the clinicopathology of bladder cancer. We
then attempted to demonstrate that laminin affects the
motility or invasion of bladder cancer cells, as it does in
other cancers. As far as we know, this is the first study that
investigates the effects of laminin 332 on clinicopathologic
parameters and in vitro invasion assays in bladder cancer.
In this study, we investigated the relationship between
laminin 332 g2, a marker of laminin 332, and tumor grade or
stage, as well as patient outcome. Then, we investigated
whether laminin 332 affected the motility and invasion of
urothelial carcinoma cells in vitro to determine how lami-
nin 332 contributes to bladder cancer invasion.
Material and methods
Patients and tumors
Thirty-five specimens of human urinary bladder were
included. The specimens were surgically resected at theDepartment of Urology, School of Medicine, Korea Univer-
sity, from 2005 to 2009. The study was approved by the
Institutional Review Board of Korea University Hospital, and
informed consent was obtained from the participants. The
surgical specimens included 13 muscle-invasive (pT2epT4)
and 22 nonmuscle-invasive (pTaepT1) carcinomas. Nine
patients had a recurrence, six had a progression, and three
died of urothelial carcinoma during the follow-up period.
Resected tissues were fixed in 10% formalin and embedded
in paraffin. Histological type and grade, and disease stage
were based on both the WHO classification criteria [20] and
the TNM system. Clinical and pathological staging were
done using 2002 TNM (tumor, lymph node, and metastasis)
classification.Immunohistochemistry
Todetect laminin 332g2, tissue sectionswere deparaffinized
with xylene, incubated with 0.3% hydrogen peroxide in
methanol, and treated with protease XXIV (Sigma, St Louis,
MO, USA) for 15minutes at room temperature. Sections were
then processed using a Cap-Plus Detection Kit (Invitrogen,
Carlsbad, CA, USA), treated with a blocking solution for 20
minutes at room temperature, incubated with monoclonal
laminin 332g2antibodyD4B5 (1:200) (Chemicon,Hampshire,
UK) overnight at 4C, and subsequently washed with Tris-
buffered saline. Sections were incubated with secondary
antibodies and streptavidin conjugated to horseradish per-
oxidase for 25 minutes, prior to incubating with 3,3-
diaminobenzidine as a substrate/chromogen for 3 minutes
and staining with hematoxylin as a nuclear counterstain for 2
minutes.Evaluation of laminin 332 g2 chain deposition
Immunoreactivity in tissues was independently judged by
two pathologists (CHK and HYC) who were blind to the clin-
ical data and other immunohistochemistry results. We
evaluated laminin 332 g2 in the BM, stromal deposition, and
cytoplasmic retention. The BM staining by D4B5 was semi-
quantitatively scored using the following scale: 1, con-
tinuous linear staining (no BM loss); 2, loss of staining in less
than 50% of the tumorestroma interface (partial BM loss);
and 3, loss of staining in more than 50% of the tumorestroma
interface (complete BM loss). Stromal deposition of laminin
332 g2 was scored as follows: 1, no deposition; 2, focal
deposition; and 3, diffuse deposition. Cellular retention of
laminin 332 g2 was scored as follows: 1, no retention; 2,
retention in some tumor cells; and 3, retention inmost tumor
cells.
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A rat bladder carcinoma cell line, NBT-II, was obtained from
the Korean Cell Line Bank (KCLB, Seoul, Korea). NBT-II cells
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Hyclone, Logan, UT, USA) supplemented with 10% fetal
bovine serum (FBS) (Hyclone), 2 mM glutamine, 100 U/mL
penicillin, and 100 mg/mL streptomycin (complete me-
dium) in a humidified atmosphere of 5% CO2 at 37
C.In vitro scratch assay
For the scratch assay, 1  105 NBT-II cells were seeded in
500 mL DMEM with 10% FBS in 24-well tissue culture plates.
After 24 hours, confluent NBT-II monolayers were scratched
with a p200 plastic pipette tip to create a cell-free zone.
Scratched cells were washed with PBS, and new DMEM with
0.5% FBS was added to each well. To observe the effect of
laminin 332 on motility, purified rat laminin 332 (Millipore
Corporation, Billerica, MA, USA) 1 mg/mL was added to each
well. After 24 hours, micrographs were taken (CKX31SF;
Olympus, Tokyo, Japan).Cell invasion assay
To analyze cell invasion, a Bodyden chamber invasion assay
was used. Cell culture inserts (BD Falcon, 8 mm pore,
transparent polyethylene terephthalate (PET) track-etched
membrane; BD Biosciences, Heidelberg, Germany) were
coated with 50 mL growth factor-reduced Matrigel (BD
Matrigel Basement Membrane Matrix; diluted 1:50 in DMEM)
and incubated overnight at 37C in 5% CO2. NBT-II cells
were suspended in culture medium at a concentration of
5  104 cells/mL in 24-well chambers. Laminin (0, 0.1, or
1 mg/mL) was added to the BD Falcon TC Companion plate
as a chemoattractant and incubated in a humidified tissue
culture incubator at 37C in 5% CO2. After 48 hours, non-
invading cells were removed from the upper surface of the
membrane. A cotton-tipped swab was inserted into the BD
BioCoat Matrigel and moved gently and firmly over the
membrane surface. Transwells were removed from the
24-well plates and stained with Hemacolor (Merck, Darm-
stadt, Germany) solution. The number of invasive cells was
counted by light microscopy (CKX31SF; Olympus, Tokyo,
Japan). Experiments were performed six times.Table 1 Tumor stage and grade of the 35 urothelial car-
cinomas used in this study.
Stage Total
Ta T1 T2 T3
Grade
Low 11 3 1 0 15 (42.9%)
High 0 8 9 3 20 (57.1%)
Total 11 (31.4%) 11 (31.4%) 10 (28.6%) 3 (8.6%) 35 (100%)Statistical analysis
Invasion assay results were analyzed by the KruskaleWallis
test with Bonferroni corrections for multiple tests. Associ-
ations between biomarkers and other clinicopathologic
parameters were evaluated using the ManneWhitney U and
KruskaleWallis tests. Survival curves were constructed
using the KaplaneMeier method and compared using the
log-rank test. The Cox proportional hazards regression
model was used for a stepwise multivariate survival analysis
(SPSS statistical software). A p value of <0.05 was consid-
ered statistically significant.Results
Patient characteristics
A total of 35 patients, 32 males and three females, were
studied. Their mean age was 68.6 years and the mean
follow-up period was 24.5 months. Fifteen patients (42.9%)
had low-grade cancer and 20 (57.1%) had high-grade can-
cer, with 11 patients in Ta (31.4%), 11 in T1 (31.4%), 10 in T2
(28.6%), and three in T3 (8.6%). Table 1 shows tumor stage
and grade distributions. Of the 35 patients, nine (25.7%)
developed a recurrence and six (17.1%) developed a pro-
gression to muscle-invasive disease. Three patients died
during the 24-month follow-up period.
Relationship between the laminin 332 g2 and
pathologic characteristics
The semiquantitative results of evaluating laminin 332 g2
distribution in patients with low- and high-grade cancer are
provided in Table 2. Of 35 patients, 13 did not lose laminin
332 g2 in the BM region (Fig. 1A), while the remaining 22
lost it in the BM region. Seventeen patients had a partial
loss of laminin 332 g2 (2 low-grade and 15 high-grade), and
five had a complete loss (2 low-grade and 3 high-grade).
Laminin 332 g2 was retained in the cytoplasm of 21 tu-
mors (3 low-grade and 18 high-grade) (Fig. 1B). Laminin 332
g2 chain was deposited in the stroma of nine tumors, with
focal deposition in seven tumors (2 low-grade and 5
high-grade) and diffuse deposition in two tumors (both
high-grade) (Fig. 1C). Loss of laminin 332 g2 from the BM
and its cytoplasmic retention differed significantly between
low- and high-grade tumors (p Z 0.002 and 0.001, respec-
tively), but stromal deposition did not (pZ 0.132) (Table 3,
ManneWhitney test).
A semiquantitative evaluation of the laminin 332 g2
distribution according to tumor stage is presented in Table
2. Seven patients with T1, nine with T2, and one with T3
had a partial loss of laminin 332 g2 in the BM, while four
with T1 and one with T3 had a complete loss. One patient
with Ta, eight with T1, nine with T2, and three with T3 had
cytoplasmic retention of laminin 332 g2 in some tumors.
Two patients with Ta, two with T1, and three with T2 had
focal stromal deposition, while one with T2 and one with T3
had diffuse deposition. There were significant differences
among patients with different tumor stages in loss from the
BM (pZ 0.001) and cytoplasmic retention of laminin 332 g2
(p Z 0.001), but not stromal deposition (p Z 0.536)
(Table 3, KruskaleWallis test).
Table 2 Semiquantitative evaluation of the laminin 332 g2 chain distribution in BM, stromal deposition, and cytoplasmic
retention according to tumor grade and stage.
Loss of laminin from the BM Cytoplasmic retention Stromal deposition Total
No Partial Complete No In some tumors No Focal Diffuse
Stage
Ta 11 0 0 10 1 9 2 0 11
T1 0 7 4 3 8 9 2 0 11
T2 1 9 0 1 9 6 3 1 10
T3 1 1 1 0 3 2 0 1 3
Grade
Low 11 2 2 12 3 13 2 0 15
High 2 15 3 2 18 13 5 2 20
Total 13 17 5 14 21 26 7 2 35
BM Z basement membrane.
Effect of laminin 332 in bladder cancer 425Association of laminin 332 g2 chain distribution
with disease progression and recurrence
During the follow-up period (mean 24.5 months), nine of 35
patients (25.7%) developed a recurrence and six (17.1%) had
a progression to muscle-invasive disease. The mean interval
to progression was 15.4 months. Overall, there were sig-
nificant differences in focal loss and cytoplasmic retention
of laminin 332 g2 between low- and high-grade tumors, as
well as between tumor stages (ManneWhitney and Krus-
kaleWallis tests). KaplaneMeier survival curves and a uni-
variate analysis using the log-rank test showed an increasedFigure 1. (A) Papillary low-grade carcinoma with no BM loss, no
chain immunostained, 200). (B) Invasive high-grade carcinoma wit
stromal deposition (laminin g2 chain immunostained, 200). (C) Inv
cytoplasmic retention, and diffuse stromal deposition (laminin g2risk of progression associated with increased cytoplasmic
retention of laminin 332 g2 (Fig. 2). Although a multivariate
analysis using the Cox proportional hazard regression
model showed no independent prognostic parameters,
cytoplasmic retention of laminin 332 g2 was the most
important parameter for predicting prognosis in our study
(p Z 0.18).
In vitro scratch and Boyden chamber invasion assay
In the in vitro scratch assay, cells had migrated from their
cluster of origin after 24 hours. Fig. 3 shows few migratingcytoplasmic retention, and no stromal deposition (laminin g2
h partial BM loss, cytoplasmic retention in some tumors, and no
asive, high-grade urothelial carcinoma with partial BM loss, no
chain immunostained, 200). BM Z basement membrane.
Table 3 Statistical relationship of the semiquantitative evaluation of the laminin 332 g2 chain distribution according to grade
and stage (p values).
Laminin ManneWhitney test KruskaleWallis test Log-rank test
Grade Stage
Loss from the basement membrane 0.002 0.001 0.108
Cytoplasmic retention 0.001 0.001 0.022
Stromal deposition 0.132 0.536 0.884
426 S.-G. Kang et al.cells in the control group, and significantly more cells
migrating from the cluster in the laminin 332-treated group
(Fig. 3).
Using a Boyden chamber invasion assay, we investigated
whether laminin 332 promoted NBT-II cell invasion. Laminin
332 added to the lower compartment of the Boyden
chambers increased the number of cells that migrated into
the lower compartment in a concentration-dependent
manner. This was repeated six times, and the mean num-
ber of invading cells, from six independent experiments,
significantly depended on the laminin concentration
(KruskaleWallis test, p < 0.001) (Fig. 4). Fig. 5 shows
laminin-untreated and laminin-treated NBT-II cells invading
the Matrigel (Fig. 5A and B).Discussion
Laminin 332 has two opposing activities, maintaining tissue
integrity and promoting cell motility, in the extracellular
matrix [9]. Laminin expression depends on the tissue, but in
general many cancers upregulate laminin 332 and it is found
at the migrating edge of tumor cells [21]. Although studies
are available on laminin 332 in a variety of tumors, such asFigure 2. KaplaneMeier survival curves and univariate
analysis using the log-rank test showed an increased risk of
progression associated with increased cellular retention of
laminin 332 g2 (p Z 0.004).squamous cell carcinoma, breast cancer, melanoma, and
colorectal cancer, few reports have examined laminin 332
in bladder cancer. Although many techniques have been
used to assess laminin 332 in cancer specimens, immuno-
histochemistry is one of the most common techniques [22].
By immunohistochemistry, normal urothelial expression of
laminin 332 g2 is restricted to the BM region in a continuous
pattern. However, there are three tumor-specific laminin
332 g2 staining patterns: laminin 332 g2 is lost from the BM,
deposited in the stroma, and retained in the cytoplasm.
These patterns have also been described in other carci-
nomas [7]. To our knowledge, only two studies have
reported on the relationship between the laminin 332 g2
and the clinicopathologic parameters of urinary bladder
cancer [18,19]. In our study, we showed that cytoplasmic
expression of laminin 332 g2 was related to tumor inva-
siveness, by KruskaleWallis tests, and to increased risk of
progression, by KaplaneMeier curves.
This study confirmed a meaningful association between
laminin 332 g2 and tumor staging or differentiation.
Although results were univariate, there was an association
between cytoplasmic retention and time to progression. A
previous study found that laminin 332 expression appeared
to be associated with the time to recurrence, but could not
clearly explain this result [19]. One possible explanation
may be that laminin 332 subunits have differential func-
tions, but there is no evidence to support this conclusion. In
another study, a univariate analysis showed that laminin
332 expression correlated with survival, but multivariate
analysis did not produce any statistically significant results
[18]. Although a Cox proportional analysis did not provide
any meaningful conclusions, intracytoplasmic retention was
indicated as the most important factor. The study found de
novo synthesis and accumulation of laminin 332 in aggres-
sive tumors by western blot, but could not provide
a mechanistic link between laminin 332 and tumor aggres-
siveness. The two possible explanations provided were that
laminin 332 caused abnormal hemidesmosomes and that it
contributed to tumor invasion through reorganization of the
extracellular matrix. However, these were not supported
by experimental evidence. There are no obvious conclu-
sions regarding bladder cancer and laminin 332, but this
and previous studies have consistently shown a clear cor-
relation between tumor stage, differentiation, and laminin
expression. Also, a correlation between laminin 332 and
time to progression seems more reasonable than that be-
tween laminin 332 and recurrence, since laminin 332 causes
invasion, which leads to progression. Much to our regret,
this relationship was not statistically significant. Future
research involving more patients may generate statistically
meaningful outcomes.
Figure 3. In vitro scratch assay. (A) Control group after 24 hours and (B) laminin 332-treated group after 24 hours.
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short arms and lacks some of the domains present in other
laminins [2,5]. Laminin 332 heterotrimers comprise a3, b3,
and g2 chains, with the g2 chain being unique to laminin
332 [22]. Therefore, the g2 chain is frequently used as
a marker. We used the g2 chain to examine the correlation
between laminin 332 and cancer malignancy. The g2 chain
exists as monomers, g2/b3 as heterodimers, and laminin
332 as heterotrimers. Differentiated gastric carcinoma cells
that form glandular structures express laminin a3, b3, and
g2. However, the g2 chain typically accumulated in the
cytoplasm of invading or budding tumor cells, without
laminin a3 or b3 [23]; thus, the g2 chain may be important
for tumor invasiveness. A recent study of the g2 monomeric
form also found that the g2 chain itself may affect cancer
motility or invasion. Of the laminin 332 subunits, g2 ap-
pears to play the largest role in tumor motility and invasion
[24]. Still, there are contrasting results and this conclusion
requires additional study. Laminin 332 g2 is thought to
affect tumor motility in a heterotrimer or a monomer. No
matter what the contribution of the g2 chain, there is
a clear correlation between g2 immunofluorescence and
tumor aggressiveness. As seen in this experiment,Figure 4. Matrigel invasion assay. NBT-II cell invasion in the
presence of varying laminin 332 concentrations (KruskaleWallis
test, p < 0.001).aggressive cancers with a higher stage or worse differenti-
ation had clearly increased laminin 332 g2 expression.
In this study, using in vitro scratch and Matrigel invasion
assays, we demonstrated that laminin 332 enhanced the
motility and invasion of NBT-II urothelial carcinoma cells.
In vivo NBT-II vesicle rat carcinoma cells secrete a laminin
332-related protein that causes scattering [25]. Also, there
is an increase in laminin g2 expression and de novo syn-
thesis of laminin in bladder cancer [18]. How the increased
laminin synthesis contributes to cancer invasion, however,
is not clear. We used NBT-II cells, which secrete laminin
332, in order to show that laminin 332 increases the motility
and invasion of this cell strain. Research on the influence of
laminin 332 and its proteolytic fragments on motility and
invasion, although somewhat controversial, has shown that
laminin 332 enhances motility by affecting cell receptors
and their associated signaling pathways. The enhanced
invasiveness of pancreatic carcinoma, colorectal adeno-
carcinoma, head and neck squamous cell carcinoma, and
melanoma cells results from enhanced laminin 332 a3b1
integrin signaling [26]. Laminin 332 a4b6 integrin can also
affect cancer cell motility [27]. Laminin 332 activity in
epithelial cell scattering and cytoskeletal reorganization
depends on the activation of the small guanosine
triphosphate (GTP)-binding protein, Rho, and is probably
independent of integrin receptors [25]. In our study,
laminin-treated NBT-II cells had lamellipodia, demonstrat-
ing cytoskeletal reorganization; however, more study is
needed to elucidate the exact signaling pathway.
Using reconstituted BM Matrigel, we demonstrated that
laminin 332 enhances invasion. Laminin 332 promotes the
production of matrix metallopeptidase 9 (MMP-9) in A375
melanomas [26]. Type IV collagenase (MMP-9) is thought to
be essential for invasive cells to degrade BM and is involved
in tumor cell invasion [28,29]. Laminin 332 has been
localized at the invasion front in colon adenocarcinomas
and likely plays a role in tumor invasion [30]. In this study,
invasion was investigated by adding laminin 332 to NBT-II
cells and examining its penetration into reconstituted BM.
According to the immunohistochemistry and invasion assay
results, synthesis and accumulation of laminin 332 increase
in aggressive tumors with higher tumor stage and grade.
This synthesis increases cytoplasmic retention, which cau-
ses tumor migration and invasion through autocrine sig-
naling. The correlation between BM loss and tumor
aggressiveness could also be explained as follows. MMP-9,
Figure 5. NBT-II cells invading Matrigel. Invading NBT-II cells in the laminin-treated group had lamellipodia and there were
significantly more cells compared with the control group. (A) Invading NBT-II cells in the control group. (B) Invading NBT-II cells in
the laminin-treated group.
428 S.-G. Kang et al.which is induced as laminin 332, degraded BM, facilitating
tumor invasion. In addition, invasive cells treated with
laminin 332 appeared to have a more mesenchymal-like
morphology. Therefore, laminin could also affect the
epithelial-to-mesenchymal transition of tumor cells.
Generally, treatment strategies for bladder cancer are
divided into radical cystectomy or intravesical treatment,
depending on the results from the initial transurethral
resection. The risk of progression to muscle-invasive dis-
ease is an important decision standard in bladder cancer
treatment [31]. Therefore, trials have focused on deter-
mining prognostic markers to predict progression; however,
until now, potential markers have had limited ability to
predict tumor recurrence, progression, development of
metastases, response to therapy, or patient survival. Since
cell migration and invasion are essential to cancer pro-
gression, these may be important for predicting progres-
sion. We demonstrated that loss of laminin 332 g2 from the
BM and cytoplasmic retention indicated urothelial carci-
noma invasiveness. As shown by both the KaplaneMeier
survival curves and the KruskaleWallis test, cytoplasmic
expression of laminin 332 g2 was associated with invasive
behavior and tumor progression of urothelial carcinoma
cells. Cellular retention of laminin 332 was the most
important prognostic parameter in the multivariate analy-
sis, although the results were not significant (p Z 0.180).
The potential limitations of our findings are that a stan-
dardized scoring protocol and criteria would have reduced
subjectivity in the immunohistochemistry studies. Addi-
tionally, the study population was small and the follow-up
period was short. Future large-scale studies using the Cox
proportional hazard regression model may provide signifi-
cant information. Despite its limitations, it is the first study
of the combined effects of laminin 332 on clinicopathologic
parameters and in vitro invasion assays in bladder cancer.
Conclusions
The present study demonstrates that expression of laminin
332 g2 is significantly correlated with the clinicopathologic
parameters of bladder cancer, and that laminin 332 can
promote NBT-II cell motility and invasion. Considering the
significance of invasiveness and progression in treatment
planning and prognosis for bladder cancer patients,investigating laminin 332 and its proteolytic subunits may
lead to the development of new targeted therapies that
can inhibit the ability of laminin 332 to drive tumor growth,
dissemination, or both. However, prior to employing this
promising prognostic marker in bladder cancer treatment,
a better understanding of laminin 332 signaling and a large-
scale, long-term population study are needed.References
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